Clinical Trials

48 enrolled

Biliary Tract Neoplasms

NCT05733598 2026-04-02

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

60 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT06282575 2026-03-24

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Phase 3 Recruiting

286 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07221253 2026-03-17

AB02

Phase 3 Recruiting

1,100 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT04900818 2026-03-05

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

330 enrolled

Adenocarcinoma Of Esophagus, Biliary Tract Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

NCT06548412 2026-01-20

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

Phase 1/2 Recruiting

50 enrolled

Biliary Tract Neoplasms

NCT06546969 2025-12-10

Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

15 enrolled

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT06564623 2025-12-05

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

25 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

NCT05451043 2025-06-26

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

62 enrolled

Biliary Tract Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT06214572 2025-04-11

RUGB

Phase 2/3 Recruiting

249 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT05222971 2025-01-28

OPTIMUM

62 enrolled

Biliary Tract Neoplasms

NCT06611345 2024-10-26

A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers

Phase NA Recruiting

60 enrolled

Biliary Tract Neoplasms

NCT03482102 2022-09-08

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

70 enrolled